Efficacy

Overview of Tabrecta (capmatinib) Efficacy in Treating Lung Cancer

Tabrecta (capmatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) and whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. This mutation can be detected by an FDA-approved test. The efficacy of Tabrecta was evaluated in a clinical trial where patients received capmatinib. The trial demonstrated a notable objective response rate (ORR), which is the percentage of patients whose tumor size reduced for a certain period. The treatment has shown to be effective in shrinking tumors and slowing the progression of the disease in patients with the specific genetic alteration.

Efficacy of Tabrecta in Different Patient Populations

The clinical trial for Tabrecta included patients who were previously treated for cancer as well as those who had not received prior treatment. The efficacy results showed that both previously treated and untreated patients with MET exon 14 skipping-mutated metastatic NSCLC responded to Tabrecta. The response rates and duration of response varied between these populations, but the data supported the use of Tabrecta across different lines of therapy in this specific subset of lung cancer patients.

Overview of Exkivity (mobocertinib) Efficacy in Treating Lung Cancer

Exkivity (mobocertinib) is another targeted therapy approved by the FDA for adult patients with NSCLC that has spread to other parts of the body and harbors specific mutations in the epidermal growth factor receptor (EGFR) gene, namely exon 20 insertion mutations. These mutations can also be identified using an FDA-approved test. The efficacy of Exkivity was established in a multi-center, non-randomized, open-label clinical trial. Patients treated with mobocertinib experienced a significant ORR, indicating that the drug was effective in shrinking tumors. The duration of response varied among patients, but the approval of Exkivity provided a new treatment option for patients with this challenging-to-treat form of lung cancer.

Efficacy of Exkivity in Previously Treated Patients

Patients enrolled in the Exkivity clinical trial had received prior treatment, including platinum-based chemotherapy and/or PD-1/PD-L1 inhibitors. Despite the presence of pre-treated disease, mobocertinib showed efficacy in inducing responses in a proportion of patients. The data suggested that Exkivity could be an effective treatment for patients with EGFR exon 20 insertion mutation-positive NSCLC who have exhausted other treatment options. The approval of Exkivity marked an important advancement in the treatment landscape for this subset of lung cancer patients.